^* The novel, fully automated workflow represents a new
Method of choice for mass spectrometric single-shot plasma analysis
without fractionation
* Bead-based plasma depletion technology enables robust,
reproducible and high-throughput quantification of almost
4,000 proteins in human plasma
* Biognosys brings this advanced workflow to researchers
Life Sciences via the company’s TrueDiscovery(TM)
Research service platform available
HOUSTON, June 08, 2023 (GLOBE NEWSWIRE) — Biognosys, a leading innovator
and provider of proteomics solutions, announces today at the American Society for
Mass Spectrometry (ASMS) Annual Conference
(https://www.asms.org/conferences/annual-conference) introducing a
advanced plasma proteomics offering that provides an in-depth,
enables unbiased analysis of plasma proteins on a large scale.
The novel workflow, which will be released today at 9:50 a.m. CDT as an oral
Presentation at the ASMS session?Industry: Trace Analysis, Quality Control,
and Automation” (industry: trace analysis, quality control and automation)
is presented (https://www.asms.org/docs/default-source/conference/final-
program-detail_2023_as-of-04-23-2023.pdf?sfvrsn=105d72c3_0), includes a
Consistently automated sample preparation, from entering the biological
Sample until generation of peptides suitable for mass spectrometry. through the
Implementation of a fully automated sample processing based on a bead
based, parallel depletion method, Biognosys has one
remarkable 35% reduction in processing time and a reduction
of the time required by 85%. In addition, the use of a bead
based workflow for plasma depletion to a significant
22% increase in protein identification and a robust and
reproducible quantification of almost 4,000 proteins in human
plasma samples allowed.
?Protein depletion is the method of choice for plasma analysis with the
Single-shot mass spectrometry because it preserves protein levels and
highest degree of depth reached without requiring further fractionation
is required,” says Dr. Lukas Reiter, Chief Technology Officer of Biognosys.
?However, conventional depletion methods are limited due to the sequential
Sample preparation time consuming. With our novel bead-based,
parallelized depletion technology, we eliminate this bottleneck and
improve reproducibility at the same time. This breakthrough makes it possible
us, the deepest unadulterated method of discovery with extraordinary
deliver throughput.”
?Blood plasma offers a unique insight into the human body,”
added dr Kristina Beeler, Chief Product Development and Marketing Officer at
Biognosys, adds.?By applying an unbiased approach that
going deeper into the proteome, we discover additional proteins and their
functional variants. This greater depth increases our chances of finding biomarkers
discover that directly reflect relevant biological mechanisms, rather than
to serve only as a backup marker.”
This novel workflow is designed to give researchers a
automated, cost-effective and reproducible solution for the
To provide plasma proteomics and allows scientists to sample more efficiently
to process and obtain reliable results on a large scale.
Biognosys places this advanced workflow over the
proprietary TrueDiscovery(TM) platform to its global customer base
which consists of over 800 biopharmaceutical and academic customers.
About Biognosys
At Biognosys, we believe that deep insight into the proteome is the key to
groundbreaking discoveries that are changing science and changing life
improve. With our versatile portfolio of proteomics solutions the next
generation, including the research service platforms
TrueDiscovery(TM), TrueTarget(TM) and TrueSignature(TM), our flagship software
Spectronaut(®) and the PQ500(TM) kit, we ensure that lessons learned from the
Proteome can be drawn to research, drug development and
to support clinical decision making. Our solutions offer one
multidimensional view of protein expression, function and structure in
all biological species and sample types. Our unique, patented
Technologies use high-resolution mass spectrometry to detect thousands of
proteins with industry-leading precision, depth, and throughput
quantify. Through our strategic partnership with Bruker (Nasdaq:
BRKR) we make proteomics accessible worldwide. Find more information
Visit biognosys.com (http://www.biognosys.com/).
About TrueDiscovery(TM)
Biognosys’ TrueDiscovery platform offers integrated proteomics solutions
for the entire drug development, from the creation of
disease profiles to studies of mechanisms of action and discovery
new biomarker.
TrueDiscovery is based on Hyper Reaction Monitoring (HRM)
Mass spectrometry, an advanced technology co-invented and developed by Biognosys
patented technology for quantifying proteins based on
independent data acquisition (DIA).
TrueDiscovery is the only platform that searches the entire proteome to
Thousands of the most important proteins, including an unlimited number of
Proteoforms to quantify. The platform enables the deepest,
unbiased profiling of tissue and biofluid proteomes
unbeatable specificity on a large scale. The data generated is in high
Dimensions reproducible and easily transferrable to clinical tests. The studies
can be performed in a GLP-certified and GCP-compliant environment
become. For more information, see truediscovery.bio
(http://truediscovery.bio/).
The source language in which the original text is published is the
official and authorized version. Translations get better
communication provided. Only the language version that is in the original
published is legally valid. You should therefore also compare translations
the original language version of the publication.
°